Schwenkreis P, Tegenthoff M
Neurologische Universitätsklinik, BG-Kliniken Bergmannsheil Bochum.
Schmerz. 2003 Oct;17(5):367-73. doi: 10.1007/s00482-003-0240-z.
This review gives insight into the potential therapeutical role of cannabinoids in neurology. Preclinical data are presented which could give a rationale for the clinical use of cannabinoids in the fields of multiple sclerosis, spasticity, epilepsy, movement disorders, and neuroprotection after traumatic head injury or ischemic stroke. Besides, clinical data (case reports, open-label and randomised controlled studies) dealing with the therapeutical use of cannabinoids in these fields are reported and discussed. At present, clinical data are insufficient to recommend the use of cannabinoids in any neurological disease as standard therapy. Several questions still have to be answered (which cannabinoid? which way of administration? stimulation of endogenous cannabinoids? separation between desired and undesired effects?), and controlled studies are still needed to clarify the potential therapeutical role of cannabinoids in neurology.
本综述深入探讨了大麻素在神经病学中的潜在治疗作用。文中呈现了临床前数据，这些数据可为大麻素在多发性硬化症、痉挛、癫痫、运动障碍以及创伤性脑损伤或缺血性中风后的神经保护领域的临床应用提供理论依据。此外，还报告并讨论了涉及大麻素在这些领域治疗用途的临床数据（病例报告、开放标签和随机对照研究）。目前，临床数据不足以推荐将大麻素用于任何神经系统疾病的标准治疗。仍有几个问题有待解答（使用哪种大麻素？采用何种给药方式？刺激内源性大麻素？区分期望和不期望的效果？），并且仍需要对照研究来阐明大麻素在神经病学中的潜在治疗作用。
